News | Venous Therapies | November 22, 2021

Early Thrombosis After Iliac Stenting for Venous Outflow Occlusion Is Related to Disease Severity and Type of Anticoagulation

Courtesy Getty Images


November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral venous occlusion prior to transition to oral anticoagulation reduces early thrombosis, according to a multi-center study.

Thrombosis following iliofemoral venous stenting is frustrating to both the patient and clinician and is an understudied phenomenon, according to a study in the November issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders.1

“Most reported data describing stent occlusion after venous intervention have included patients across the full spectrum of venous disease. Including patients with non-thrombotic disease and limited anatomic involvement as well as patients with more extensive disease has prevented the identification of specific variables relating to the outcomes for either group of patients separately,” said principal investigator William Marston, M.D., from the University of North Carolina.

“In this study, we investigated a patient cohort with venous outflow occlusion requiring recanalization before stenting to determine the outcomes after intervention. We focused on the variables associated with early stent thrombosis in this high-risk segment of patients presenting with iliocaval outflow obstruction,” he continued.

Marston’s team retrospectively studied patients undergoing iliofemoral venous stenting at their institution (11 practitioners, two hospitals) from 2010 to 2020.

Only patients with type III (single segment) and type IV (multiple segment) iliofemoral venous occlusions were included.

A total of 106 patients were studied and had the following characteristics:

  • Age 50 +/- 14 years

  • Type III (41%) versus type IV (59%) disease pattern

  • One fourth with known hypercoagulable state

Treatment included:

  • Mean stent length 177 +/- 63mm

  • Antiplatelet therapy in 53%

  • Anticoagulation in 95%

  • Anticoagulation involving LMWH


    - As a bridge (<10 days) to warfarin (n=9), or


    - For two to four weeks before transition to oral anticoagulation (n=41)

  • Anticoagulation with a DOAC (n=39)

Three months following the procedure, occlusion of the stented region occurred in 26%. The observed three-year patency rates were primary, 59%, and secondary, 76%.

Risk factors for early (within three months) stent thrombosis were:

  • Type IV disease (odds ratio 4.6)

  • Hypercoaguable state (odds ratio 3.8)

  • Treatment with LMWH for >10 days was associated with lower odds (0.01) of early thrombosis.

“Patients with more extensive disease (type IV) experienced a greater incidence of thrombosis,” Marston said. “Therefore, studies that group non-thrombotic with post-thrombotic patients who have undergone stenting will be less able to identify the best treatment protocols.

“No consensus has been reached regarding the optimal postoperative anticoagulation therapy for these patients. Our study suggests that extended use of LMWH reduces early thrombosis.”

About the Society for Vascular Surgery

The Society for Vascular Surgery is the leading not-for-profit, professional medical society on establishing causes and treatments for vascular disease. SVS seeks to advance excellence and innovation in vascular health through education, advocacy, research and public awareness and is composed of specialty-trained vascular surgeons who are dedicated to providing comprehensive care for vascular disease. For more information visit www.vascular.org

Reference:

1 William A. Marston, Sydney E. Browder, Kathleen Iles, Anna Griffith, Katharine L. McGinigle. Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity and type of anticoagulation. Journal of Vascular Surgery: Venous and Lymphatic Disorders Published March 2, 2021. DOI: https://doi.org/10.1016/j.jvsv.2021.02.012.

https://www.jvsvenous.org/article/S2213-333X(21)00098-6/fulltext?utm_source=JVSVL&utm_medium=PressRelease&utm_campaign=Promotion

 


Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now